This study is testing a new way to give whole brain radiation therapy (WBRT) called Pulsed Reduced Dose-Rate (PRDR) technique, along with a medication called memantine, for people with brain metastases (cancer that has spread to the brain). The goal is to see if this approach is safe and can help reduce memory and thinking problems that can sometimes happen after WBRT. You could be eligible if you are at least 18 years old, have brain metastases from a solid tumor, and meet certain health criteria. The main goal is to see if patients can successfully complete the PRDR WBRT treatment.

Study design

This is a Phase II study, meaning it's an early-stage study looking at safety and effectiveness. It's a single-arm study, so all 53 participants will receive the same treatment.

What's involved

You would receive PRDR WBRT within 14 days of joining the study, given in 10 daily sessions. You would also start taking memantine orally, either two days before, one day before, or no later than the fourth WBRT session.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint for successful completion of PRDR WBRT treatment is measured at 5 days. Other clinical outcomes will also be collected.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.